XTL Biopharmaceuticals Ltd.
Clinical-stage biopharmaceutical company developing drugs for autoimmune diseases.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Manufacturing
Description
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-07-23 01:14 |
Results of the Annual and Extraordinary Meeting held on July 22, 2024
|
English | 36.3 KB | ||
| 2024-06-13 01:24 |
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
|
English | 2.7 MB | ||
| 2024-06-13 01:24 |
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
|
English | 1.4 MB | ||
| 2024-06-13 01:24 |
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
|
English | 2.4 MB | ||
| 2024-06-13 01:24 |
Immediate Report of Meeting To Be Held On July 22, 2024,PROXY STATEMENT
|
English | 141.1 KB | ||
| 2024-06-05 18:57 |
Defenitive agreement for the purchase of The Social Proxy
|
English | 340.4 KB | ||
| 2024-06-05 18:57 |
Defenitive agreement for the purchase of The Social Proxy
|
English | 36.3 KB | ||
| 2024-05-13 19:43 |
Financial results for the three months ended March 31, 2024
|
English | 150.0 KB | ||
| 2024-05-13 19:43 |
Financial results for the three months ended March 31, 2024
|
English | 36.3 KB | ||
| 2024-05-01 01:57 |
Results of Extraordinary General Meeting of Shareholders held
on April 30, 2024
|
English | 132.2 KB | ||
| 2024-05-01 01:57 |
Results of Extraordinary General Meeting of Shareholders held
on April 30, 2024
|
English | 36.2 KB | ||
| 2024-04-30 23:54 |
20F FOR 2023
|
English | 4.5 MB | ||
| 2024-04-30 23:54 |
20F FOR 2023
|
English | 36.3 KB | ||
| 2024-03-22 00:29 |
FORM 6-K- Immediate Report of Meeting at 4:00 p.m. (Israel Time), April 30, 2024
|
English | 1.1 MB | ||
| 2024-03-22 00:29 |
FORM 6-K- Immediate Report of Meeting at 4:00 p.m. (Israel Time), April 30, 2024
|
English | 1.1 MB |
Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for XTL Biopharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
